A Study of Prevalence of Diastolic Dysfunction in Rheumatoid Arthritis Patients by Ramya, J
1 
 
A STUDY ON PREVALENCE OF DIASTOLIC 
DYSFUNCTION IN RHEUMATOID ARTHRITIS 
PATIENTS 
 
DISSERTATION SUBMITTED FOR 
 
M.D GENERAL MEDICINE 
BRANCH – I 
APRIL 2012 
 
 
 
 
     
THE TAMILNADU 
DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
 
2 
 
                                  
 
                                           CERTIFICATE 
 
This is to certify that this dissertation titled “A STUDY ON 
PREVALENCE OF DIASTOLIC DYSFUNCTION IN RHEUMATOID 
ARTHRITIS PATIENTS” submitted by                 DR RAMYA. J  to the 
faculty of General Medicine, The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai in partial fulfillment of the requirement for the award of 
MD degree Branch I General Medicine, is a bonafide research work carried 
out by her under our direct supervision and guidance. 
 
 
DR. R . BALAJINATHAN, M.D                 DR.MOSES.K. DANIEL, M.D. 
Professor of Medicine,                                    Professor and Head, 
Chief, IV Medical Unit,                                  Department of Medicine, 
Department of Medicine,                                Madurai Medical College, 
Madurai Medical College,                              Madurai. 
Madurai. 
. 
 
 
 
3 
 
 
 
DECLARATION 
 
I, Dr. Ramya. J, solemnly declare that the dissertation titled “A 
STUDY ON PREVALENCE OF DIASTOLIC DYSFUNCTION IN 
RHEUMATOID ARTHRITIS PATIENTS” has been prepared by me. 
This is submitted to The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai, in partial fulfillment of the rules and regulations for 
the award of MD degree (Branch I) General Medicine. 
 
 
Place: Madurai 
Date:                                                                    Dr Ramya. J 
 
 
 
 
 
 
 
 
 
4 
 
ACKNOWLEDGEMENT 
 
 
       At the outset, I wish to thank our DEAN  for permitting me to use the 
facilities of Madurai Medical College and Government Rajaji Hospital to 
conduct this study. 
      My beloved Head of the Department of Medicine, PROF MOSES .K. 
DANIEL, M.D. has always guided me, by example and valuable words of 
advice and has always given me his moral support and encouragement 
throughout the conduct of the study and also during my post graduate course. I 
owe my sincere thanks to him. 
      I also owe my sincere thanks to my unit chief and my guide 
PROF. R.BALAJINATHAN, M.D., for his guidance and advice throughout 
the study. 
Knowledge and kindness abounds my beloved teachers   
Dr.S.Vadivelmurugan M.D.,  Dr. V.T.Premkumar M.D.,  
Dr Natarajan M.D ,. Dr Bhagya lakshmi M.D,. Dr Sangumani . J M.D.,  I 
owe them a lot and sincerely thank them. 
I offer my sincere thanks to Dr. Arul Raja Murugan M.D., Assistant 
professor, Rheumatology  for his constant encouragement and guidance 
throughout the study period. 
 
5 
 
I offer my heartfelt thanks to my Assistant Professors 
Dr.V.N. Alaga Venkatesan M.D., Dr.G. Gurunamasivayam M.D.,  for their 
constant encouragement, timely help and critical  suggestions throughout the 
study and also for making my stay in the unit both informative and pleasurable. 
I also offer my thanks to Prof. A. R Janarthanan M.D,D.M., HOD 
Department of cardiology for allowing me the use of  echocardiographic 
facilities. I also offer my sincere thanks to Assistant Professors and Post 
Graduates of Department of Cardiology for their help and guidance. 
I profusely thank the Department of Microbiology, Pathology and 
Biochemistry for their cooperation and support. 
My family and friends have stood by me during my times of need. Their 
help and support have been invaluable to the study. 
My patients, who form the most integral part of the work, were always 
kind and cooperative. I cannot but pray for their speedy recovery and place this 
study as a tribute to them and to the numerous others likely affected. 
Above all I thank the Lord Almighty for His kindness and benevolence.  
 
 
           
                                    
 
6 
 
 
CONTENTS 
 
S NO.             TOPIC                            PAGE NO 
1.          INTRODUCTION      1 
2.   REVIEW OF LITERATURE    6 
3.   AIMS AND OBJECTIVES     23 
4.   MATERIALS AND METHODS    24 
5.   RESULTS AND ANALYSIS    30 
6.   DISCUSSION       44 
7.   CONCLUSION       50 
    8.    SUMMARY      52 
    9.   APPENDIX 
BIBLIOGRAPHY 
PROFORMA 
MASTER CHART 
 
ETHICAL COMMITTEE  
APPROVAL FORM 
 
ABSTRACT 
Aims : The aim of this study was to evaluate the prevalence of diastolic dysfunction in 
rheumatoid arthritis patients and to compare them with age and  sex matched controls.  The 
correlation between diastolic dysfunction and disease activity was looked for. 
Methods : The study was a cross sectional  study involving 40 patients (8 maleand 32 
female) with RA without clinically evident heart disease and 20 healthy subjects (16 female 
and 4 male) who served as a control group. Both groups were matched for age and sex. 
Echocardiographic and Doppler studies were conducted in all patients with RA and control 
subjects. 
Results : Our study  shows that patients with RA have a higher prevalence of diastolic 
dysfunction (40%) than non-RA subjects (10%) . The ejection fraction was preserved in all 
patients. The result in this study showed E/A ratio in RA patients was 1.135 (0.822–1.448) 
and in the control group was 1.305 (1.122–1.487). Dt in RA patients was longer compared to 
the control population (180 ms ± 27..77vs. 160.5 ms ± 11.95) with a significant p value. ). 
The E/E′ index of RA patients was 8.447 ± 2.32 which was higher compared to the study 
population 7.946+/- 0.43. The LA volume indexed to body surface area was significantly 
higher in patients of RA compared to study group. It was 23.03+/- 7.53 in study group as 
compared to 18.18+/- 2.44 with a significant p value of 0.007. This study showed significant 
correlations between duration of disease, disease severity and echocardiographic 
measurements.There were no statistically significant differences between diastolic 
dysfunction and normal diastolic function groups in term of  age of the patient, duration of 
disease, DAS 28, rheumatoid factor.  
Conclusion:  Prevalence of diastolic dysfunction in the rheumatoid arthritis group (40%) 
was higher compared to controls (10%). LV diastolic function had  significant correlation 
with RA disease severity and duration of disease. 
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INTRODUCTION 
       Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory 
disorder of unknown aetiology that involves not only the joints but also 
other extra-articular organs. The prevalence of RA is ~0.8% of the 
population (range 0.3–2.1%); women are affected approximately three 
times more often than men (1). In India, the prevalence of rheumatoid 
arthritis (0.75%) is similar to that in the west (7,8). 
Insights gained by a wealth of basic and clinical research over the 
past two decades have revolutionized the way we make the diagnosis and 
manage a case of RA. Serum antibodies to cyclic citrullinated peptides 
(anti-CCPs) are now recognized to be a valuable biomarker of diagnostic 
and prognostic significance. The clinical diagnosis of RA is largely based 
on signs and symptoms of a chronic inflammatory arthritis, with laboratory 
and radiographic results providing important supplemental information. In 
2010, a collaborative effort between the American College of 
Rheumatology  (ACR) and the European League Against Rheumatism 
(EULAR) revised the 1987 ACR classification criteria for RA in an effort 
to improve early diagnosis with the goal of identifying patients who would 
benefit from early introduction of disease-modifying therapy(1). 
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  The new criteria include a positive test for serum anti-cyclic 
citrullinated peptide antibodies as an item, which carries greater specificity 
for the diagnosis of RA than a positive test for rheumatoid factor. The 
newer classification criteria also do not take into account if the patient has 
rheumatoid nodules or radiographic joint damage because these findings 
occur rarely in early RA. It is important to emphasize that the new 2010 
ACR-EULAR criteria are "classification criteria" as opposed to 
"diagnostic criteria" and serve to distinguish patients at the onset of 
disease with a high likelihood of evolving into a chronic disease with 
persistent synovitis and joint damage(1). In our study the patients have 
been diagnosed using the 1987 ACR classification criteria. 
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The 1987 Revised Criteria for the Classification of RA 
1.  a. Four of seven criteria are required to classify a patient as having 
rheumatoid arthritis (RA). 
  b. Patients with two or more clinical diagnoses are not excluded. 
2. Criteria
a
  
  a. Morning stiffness: Stiffness in and around the joints lasting 1 h before 
maximal improvement. 
  b. Arthritis of three or more joint areas: At least three joint areas, observed by 
a physician simultaneously, have soft tissue swelling or joint effusions, not just 
bony overgrowth. The 14 possible joint areas involved are right or left 
proximal interphalangeal, metacarpophalangeal, wrist, elbow, knee, ankle, and 
metatarsophalangeal joints. 
  c. Arthritis of hand joints: Arthritis of wrist, metacarpophalangeal joint, or 
proximal interphalangeal joint. 
  d. Symmetric arthritis: Simultaneous involvement of the same joint areas on 
both sides of the body. 
  e. Rheumatoid nodules: Subcutaneous nodules over bony prominences, 
extensor surfaces, or juxtaarticular regions observed by a physician. 
  f. Serum rheumatoid factor: Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result has been positive in less 
than 5% of normal control subjects. 
 a
Criteria a–d must be present for at least 6 weeks. Criteria b–e must be 
observed by a physician.  Source: From Arnett et al.(28) 
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Classification Criteria for Rheumatoid Arthritis - 2010 ACR – 
EULAR 
Score 
Joint 
involvement  
  
  
  
1 large joint (shoulder, elbow, hip, knee, ankle) 0 
2–10 large joints 1 
1–3 small joints (MCP, PIP, Thumb IP, MTP, wrists) 2 
4–10 small joints 3 
>10 joints (at least 1 small joint) 5 
Serology 
  
  
Negative RF and negative ACPA 0 
Low-positive RF or low-positive anti-CCP antibodies (3 
times ULN) 
2 
High-positive RF or high-positive anti-CCP antibodies 
(>3 times ULN) 
3 
Acute-phase 
reactants  
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Duration of 
symptoms 
 <6 weeks 0 
6weeks 1 
 
Note: These criteria are aimed at classification of newly presenting patients who 
have at least 1 joint with definite clinical synovitis that is not better explained 
by another disease. 
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Abbreviations: 
 
 CCP  -  cyclic citrullinated peptides;  
CRP  - C-reactive protein;  
ESR   - erythrocyte sedimentation rate;  
IP  -  interphalangeal joint;  
MCP  - metacarpophalangeal joint 
MTP  - metatarsophalangeal joint;  
PIP  - proximal interphalangeal joint; RF, rheumatoid factor; 
ULN  - upper limit of normal. 
Source: Neogi et al: Arthritis Rheum 62:2569, 2010 (29). 
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                                          REVIEW OF LITERATURE  
   Long term survival of patients with rheumatoid arthritis (RA) is 
shorter compared with the general population or control subjects without 
RA (2). The most common cause of death in patients with RA is 
cardiovascular disease. Furthermore, congestive heart failure (including 
both systolic and diastolic dysfunction) occurs at an approximately 
twofold higher rate in RA than in the general population(4). The presence 
of elevated serum inflammatory markers appears to confer an increased 
risk of cardiovascular disease in this population as reported in many 
studies (3,4,5) . However, cardiac disease is often clinically silent and is 
rarely a severe life threatening complication in RA. 
            
Rheumatoid arthritis is associated with increase in mortality due to 
acceleration of coronary and cerebrovascular atherosclerosis(11). Overall, 
RA patients have shorter life spans compared to the general population. 
The mortality rates in patients with RA are 1.5–1.6-fold higher than in the 
general population. The attributed causes of death appear overall similar to 
the general population, with cardiovascular disease being the most 
common attributed cause of death, followed by infection, pulmonary and 
renal disease (12). This fact was supported by a recent study done in 
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Sweden that found that, there was a significant increase in mortality 
among patients with RA compared with the general population and the 
most common cause of death in RA patients was cardiovascular events 
(12,13,14). RA patients are also more prone to atherosclerosis, myocardial 
infarction and stroke (14,15,16). Other possible complications that may 
arise include: pericarditis, myocarditis, atrioventricular block, valvular 
regurgitation, rheumatoid nodule, left ventricular failure, valvulitis and 
fibrosis (3). 
 The pathophysiology behind increased incidence of cardiovascular 
events in patients with RA is of considerable research interest and is vital 
for development of preventive strategies in future.  Chronic inflammation 
is postulated to enhance the development of atherosclerosis in patients 
with RA. Pro-inflammatory cytokines, the levels of which are elevated in 
RA, have been found to play an important role in the development and 
progression of atherosclerosis. Now considered an inflammatory disease, 
atherosclerosis involves the production of pro-inflammatory cytokines by 
immune cells, such as monocytes, macrophages, and T-cells, at sites of 
atherosclerotic lesions, as well as by endothelial and smooth muscle cells. 
The chronic systemic inflammation seen in RA and systemic lupus 
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erythematosus (SLE) may further amplify atherosclerosis through 
endothelial dysfunction and oxidative stress. Pro-inflammatory cytokines 
(e.g. tumour necrosis factor α [TNF-α] and interleukin-1 [IL-1]), expressed 
by affected joints in RA, may act on other tissues and organs and promote 
atherosclerosis. (3)(30). The risk of heart failure can be partially explained 
by traditional cardiovascular risk factors and also involves disease-related 
factors such as high plasma interleukin (IL-6), C-reactive protein (CRP) 
and TNF-α levels, vasculitic processes and RA itself. (17)  
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Pathophysiologic mechanisms that may be involved in accelerated 
atherosclerosis and congestive cardiac failure associated with rheumatoid 
arthritis. 
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   The cardiovascular manifestations of RA can take many forms. 
Clinically apparent heart disease attributable to rheumatoid process was 
previously thought to be rare. But of late because of advances in 
investigational facilities, various necropsy studies; several important 
studies have been performed which have highlighted the importance of 
cardiac involvement by RA.  It is now reported that 70% of patients with 
nodular disease and 40% of patients with non-nodular RA have some 
cardiac involvement, including valve thickening or incompetence (3,10).
 
   Of all the cardiovascular manifestations, two processes need our 
considerable attention here. First being accelerated atherosclerosis. 
Patients with prolonged RA have more atherosclerosis than patients of the 
same age with more recent disease onset (3,17). Persistent low grade 
inflammation associated with elevated levels of pro-inflammatory 
cytokines have been implicated for this increased risk (18). Second process 
which is of interest to our study will be elaborated below.  
      Cardiac failure is the result of either systolic or diastolic dysfunction or 
both. Left ventricular diastolic dysfunction is usually attributable to 
common structural abnormalities such as hypertrophy or interstitial 
fibrosis and impaired myocyte relaxation resulting from ischemia. 
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Compared with persons without RA, patients with RA have twice the risk 
of developing CHF (4). A large population based study conducted by 
Nicola et,al concluded that patients with RA have twice the risk of 
developing CHF compared with subjects without RA. This excess risk 
remained even after fully adjusting for CV risk factors and ischemic heart 
disease, and was higher in patients with RA who were RF positive than in 
those who were RF negative.  
They observed that the  increased risk of CHF among patients with 
RA is not attributable to an increased frequency or effect of either CV risk 
factors (i.e., hypertension, smoking, diabetes) or clinical ischemic heart 
disease, but rather, through independent RA or RA-disease associated 
factors (5). The risk of heart failure can only be partially explained by 
traditional cardiovascular risk factors and also involves disease-related 
factors such as high plasma interleukin (IL-6), C-reactive protein (CRP) 
and TNF-α levels, vasculitic processes and RA itself(17).  In the large and 
well-studied population of rheumatoid patients at the Mayo Clinic, patients 
were followed until death, migration from Olmstead County, or 2001. The 
data showed that congestive heart failure was more important than 
ischemic heart disease as cause of death (5).  Even in RA patients without 
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clinically evident cardiovascular disease, the left ventricular diastolic 
function and the right ventricular diastolic function are reduced(6,3). It has 
also been recently shown that RA subjects with HF have fewer typical 
signs and symptoms of HF and are more likely to have preserved ejection 
fraction (EF≥50%) compared to non-RA subjects with HF (18). Among 
RA subjects, the presentation of heart failure is more subtle, myocardial 
function is more likely preserved, while mortality from heart failure is 
significantly higher(19,20). Diastolic dysfunction in asymptomatic RA 
patients gradually progressing over years to overt cardiac failure has been 
presented as the most likely explanation of this form of presentation (18).               
   There are a number of studies that have reported the presence of 
diastolic dysfunction in patients with RA without clinically evident cardiac 
disease(21,22,23).  Structural and functional alterations of the myocardium 
have been reported in numerous controlled, cross-sectional studies of RA 
subjects without known cardiovascular disease, suggesting impairment of 
diastolic function (4,5,15,17,20). These findings indicate that, compared to 
non-RA subjects, heart failure in RA may be more often related to 
diastolic dysfunction in comparison to the general population. Diastolic 
dysfunction is frequent and it can be asymptomatic for a long time. It can 
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be considered as the first step in the pathogenic pathway leading to heart 
failure. Other cardiovascular involvement such as myocardial fibrosis, 
granulomatous nodules, myocarditis, arteritis, amyloidosis and the use of 
cardiotoxic drugs, are also believed to be responsible for the development 
of diastolic impairment. At present, however, the direct effects of 
inflammatory cytokines (and rheumatoid arthritis therapies) on the 
myocardia of rheumatoid arthritis patients are incompletely understood. 
  Diastolic heart failure normally occurs before patients develop 
systolic heart failure. It is important to recognize diastolic heart failure 
(dysfunction) in any patient, particularly in RA, in order to retard 
progression of heart failure (20).  The knowledge of diastolic dysfunction 
is beneficial in improving survival rates in RA patients. 
A  recently concluded study by Stephania Magda et al – CARRE 
study concluded that cardiovascular affection in RA is much higher 
compared to normals and is similar to that of diabetics(44). EULAR 
evidence based recommendations for management of rheumatoid arthritis 
suggest the following recommendations (45,46).  
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Recommendations :  
Level of evidence               Strength of  recommendation 
1.  RA should be regarded as a condition associated with higher risk for 
CV disease. This may also apply to AS and PsA, although the 
evidence base is less. The increased risk appears to be due to both an 
increased prevalence of traditional risk factors and the inflammatory 
burden 2b–3 B 
2.  Adequate control of disease activity is necessary to lower the CV 
risk 2b–3 B 
3.  CV risk assessment using national guidelines is recommended for all 
patients with RA and should be considered annually for all patients 
with AS and PsA. Risk assessments should be repeated when 
antirheumatic treatment has been changed3–4 C 
4.  Risk score models should be adapted for patients with RA by 
introducing a.  1.5 multiplication factor. This multiplication factor 
should be used when the patient with RA meets two of the following 
three criteria: 3–4 C 
– Disease duration of more than 10 years 
– RF or anti-CCP positivity 
– Presence of certain extra-articular manifestations 
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5. TC/HDL cholesterol ratio should be used when the SCORE model is 
used 3 C 
6.    Intervention should be carried out according to national guidelines 3 C 
7.  Statins, ACE inhibitors and/or AT-II blockers are preferred 
treatment options 2a–3 C-D 
8.  The role of coxibs and most NSAIDs in CV risk is not well 
established and needs further investigation. Hence, we should be 
very cautious about prescribing them, especially for patients with a 
documented CV disease or in the presence of CV risk factors2a–3 C 
9.  Corticosteroids: use the lowest dose possible 3 C 
10.  Recommend smoking cessation 3 C 
[ACE, angiotensin-converting enzyme; anti-CCP, anti-cyclic 
citrullinated peptide; AT-II, angiotensin II; coxibs, cyclo-oxygenase-
2inhibitors; HDL, high-density lipoprotein; NSAIDs, non-steroidal anti-
inflammatory drugs; RF, rheumatoid factor; SCORE, SystematicCoronary 
Risk Evaluation; TC, total cholesterol]. 
Recommends 
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Doppler echocardiography is a sensitive and non-invasive method of 
detecting cardiac abnormalities and systolic and/or diastolic function (6). 
About 50% of patients with heart failure have preserved LVEF. 
Assessment of diastolic function requires an understanding of diastology 
and various means to evaluate diastolic function. Currently, 
echocardiography is the best noninvasive way to evaluate diastolic 
function and to estimate filling pressures. M-mode, two-dimensional, and 
Doppler (blood flow, tissue, and color) echocardiography are all helpful in 
evaluating diastolic function. Recently, the ASE and the European 
Association of Echocardiography (EAE) published a guideline for 
assessment of diastolic function by echocardiography which has 
standardised this previously ambiguous method of investigating diastolic 
dysfunction (24). 
The grading of the diastolic filling pattern (or diastolic dysfunction) 
is based on several parameters (see figure below). In most (if not all) 
cardiac diseases, the initial diastolic abnormality is impaired relaxation. 
With further progression of disease and a mild to moderate increase in LA 
pressure, the mitral inflow velocity pattern appears similar to a normal 
filling pattern (pseudonormalized). With further decrease in LV 
23 
 
compliance and increase in LA pressure, diastolic filling becomes 
restrictive. Most patients with restrictive filling are symptomatic and have 
a poor prognosis unless the restrictive filling can be reversed by treatment. 
However, restrictive filling may be irreversible and represent the end stage 
of diastolic heart failure. Therefore, diastolic dysfunction can be graded 
according to the diastolic filling pattern (26). The grading scheme is mild 
or grade I (impaired relaxation pattern), moderate or grade II (PNF), and 
severe (restrictive filling) or grade III (figure below). This scheme was an 
important predictor of all-cause mortality in a large epidemiologic study 
(25). 
Grade 1 (mild dysfunction): impaired relaxation with normal filling  
pressure. 
Grade 2 (moderate dysfunction): pseudonormalised mitral inflow pattern. 
Grade 3 (severe reversible dysfunction): reversible restrictive (high filling 
pressure) 
 Grade 4 (severe irreversible dysfunction): irreversible restrictive (high 
filling pressure) (24). 
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   In patients with mild diastolic dysfunction, the mitral E/A ratio is  
0.8, DT is  200 ms, IVRT is  100 ms, predominant systolic flow is seen in 
pulmonary venous flow (S / D), annular e‟ is  8 cm/s, and the E/e‟ ratio is  
8 (septal and lateral). 
In patients with moderate diastolic dysfunction (grade II), the mitral 
E/A ratio is 0.8 to 1.5 (pseudonormal) and decreases by  50% during the 
Valsalva maneuver, the E/e‟ (average) ratio is 9 to 12, and e‟ is  8 cm/s. 
 With severe diastolic dysfunction (grade III), restrictive LV filling 
occurs with an E/A ratio  2, DT  160 ms, IVRT  60 ms, systolic filling 
fraction  40%, mitral A flow duration shorter than Ar duration, and 
average E/e= ratio  13 (or septal E/e‟ 15 and lateral E/e‟  12). LV filling 
may revert to impaired relaxation with successful therapy in some patients 
(grade IIIa), whereas in others, LV filling remains restrictive (grade IIIb). 
Because the reversibility of restrictive filling usually cannot be assessed at 
one clinical setting, grade 4 dysfunction was not used in the ASE and EAE 
recommendation(26). 
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Assessment of left atrial volume  is clinically important, because 
there is a significant relation (39) between LA remodeling and 
echocardiographic indices of diastolic function. Doppler velocities and 
time intervals reflect filling pressures at the time of measurement, whereas 
LA volume often reflects the cumulative effects of filling pressures 
overtime. LA volume index   >/34 mL/m2 is an independent predictor of 
death, heart failure, atrial fibrillation, and ischemic stroke(40). However, 
one must recognize that dilated left atria may be seen in patients with 
bradycardia and 4-chamber enlargement, anemia and other high-output 
states, atrial flutter or fibrillation, and significant mitral valve disease, in 
the absence of diastolic dysfunction. Likewise, it is often present in elite 
athletes in the absence of cardiovascular disease (26). 
In normal young subjects, LV elastic recoil is vigorous because of 
normal myocardial relaxation; therefore, most filling is completed during 
early diastole. Thus, the E/A ratio is usually 1.5 or higher, DT is 160 to 
240 milliseconds (septal), e′ is 10 cm/sec or higher, E/e′ is less than 8, and 
Vp is 50 cm/sec or higher. With normal myocardial relaxation, the 
longitudinal mitral annulus diastolic velocity pattern mirrors that of normal 
mitral inflow: early diastolic velocity (e′) is higher than late diastolic 
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velocity (a′). Lateral annulus velocity is always higher (normal, 
>15 cm/sec) than septal e′. Thus, e′ increases with exercise in healthy 
subjects so that E/e′ is similar at rest and with exercise (usually <8).[45] 
With aging, there is a gradual decrease in the rate of myocardial relaxation 
as well as in elastic recoil, resulting in slower decline of LV pressure, and 
filling becomes slower, producing a diastolic function pattern similar to 
grade 1 dysfunction. At roughly the age of 65 years, E velocity approaches 
A velocity, and in persons older than 70 years, the E/A ratio is usually less 
than 1.0. The reversal of e′/a′ occurs about 10 to 15 years earlier than that 
of E/A. Pulmonary venous flow velocities show similar changes with 
aging; diastolic forward flow velocity decreases as more filling of the left 
ventricle occurs at atrial contraction and systolic forward flow velocity 
becomes more prominent. Measurements of diastolic function in 1012 
subjects without a history of cardiovascular disease or abnormal two-
dimensional echocardiograms showed that all diastolic function 
parameters are associated with age(24).  
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AIM OF THE STUDY 
  To evaluate the prevalence of diastolic dysfunction in patients with 
rheumatoid arthritis and to compare them with age and sex matched 
controls. 
 To look  for  correlation between degree of diastolic dysfunction and  
1. duration of the disease 
2. severity of the disease  
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                              MATERIALS AND METHODS 
 
   Ours was a cross sectional study carried out for a period of 1 year. 
The setting was Department of Medicine, Govt Rajaji Hospital. Approval 
was obtained from the ethical committee headed by the Dean, Govt Rajaji 
Hospital.  Informed written consent was obtained from all patients. Study 
population consisted of patients attending Rheumatology OP who were 
randomly selected. The data obtained was analysed using EPI Info 2002 
statistical software. 
   The study was carried out on 40 patients attending the 
Rheumatology out patient department of Madurai Medical College with an 
established diagnosis of RA, as defined by the American College of 
Rheumatology 1987 criteria. 20 age and sex matched controls were 
selected from same population. 
   Patients were considered seropositive if the rheumatoid factor (Latex 
agglutination test) was positive (>8 IU/L) on atleast one occasion during 
the course of their disease. 
    All patients had been treated with nonsteroidal anti-inflammatory 
drugs (diclofenac, 100-150 mg/day) daily. Treatment with a DMARD was 
initiated when a diagnosis of RA was made. All the patients included in 
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our study were receiving one or more DMARD including chloroquine, 
sulfasalazine and methotrexate. Some of them were on low dose steroids 
(5-15mg/day) depending on severity of symptoms. 
INCLUSION CRITERIA : 
 Patients who satisfied the American College of Rheumatology 1987 
criteria. 
 Age group -  17 to 60 years irrespective of the sex 
 Any duration of illness 
EXCLUSION CRITERIA : 
 Systemic hypertension 
 Diabetes mellitus 
 Ischemic heart disease 
 Valvular heart disease 
 Chronic systemic illness 
 Chronic smoker 
 Any other structural heart disease 
 Obesity (BMI >30) 
 Pregnacy 
 ECG s/o left ventricular hypertrophy or any pathological q waves.  
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A questionnaire prepared noted the duration of RA, early morning 
joint stiffness, extra-articular complications, personal history including 
smoking, medications, domestic pets and occupation. The use of current 
and previous disease-modifying drugs, corticosteroid use, and. Analgesics 
was noted. Cigarette consumption was evaluated in pack years (1 pack yr 
= 20 cigarettes/day for 1 yr). 
 A detailed clinical examination consisting of  recording of 
anthropometric parameters and blood pressure , the number of tender and 
swollen joints and systemic examination was performed. All patients had 
venous blood taken for full blood count, renal and liver function, lipid 
profile, serum uric acid, erythrocyte sedimentation ratio,  C-reactive 
protein and immunological investigations included rheumatoid factor 
(latex agglutination test). 
All patients underwent  chest radiography, electrocardiogram (ECG), 
echocardiography. 
The activity of the disease was assessed using DAS 28(Disease 
activity score)Disease activity score is a composite score using tender and 
swollen joints count , ESR and patients global assessment activity using a 
100 mm visual analogue scale. 
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DAS28=0.56 √(no.of tender joints) + 0.28 √(no.of swollen joints) 
+0.70 log(ESR)+0.014(global assessment in mm). 
 
Classification 
Mild   <3.2 
Moderate  3.2-5.1 
Severe  >5.1 ( Minimum score :0; Maximum score : 9 ) 
Parameters used in Disease activity score: 
(1) Total 28 joint count for tenderness 
(2) Total 28 joint for swelling 
(3) ESR in mm in first hour 
(4) Patient assessment of global health using a 100mm visual analogue 
scale ranging from 0(very good) to 100 (very poor ) 
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ECHOCARDIOGRAPHY : 
Two-dimensional and M mode echocardiography was performed 
using ALOKA echocardiogram. One senior cardiologist performed the 
echocardiography. The cardiologist was blinded to clinical details of the 
patients. The following variables were assessed using the 2 – dimensional 
echo -  left ventricular end-diastolic diameter, left ventricular end-systolic 
diameter, left atrial volume, left ventricular mass. 
 Fractional shortening and ejection fraction were calculated 
according to Simpson‟s formula. Special attention was paid to the structure 
of the mitral, aortic, tricuspid, and pulmonary valves (different grades of 
regurgitation and stenosis were assessed), and the pericardial space to 
detect pericardial effusion. 
Doppler echocardiography was used to obtain transmitral flow from 
the apical four-chamber view to assess filling patterns. The following 
variables were examined as parameter of left ventricular filling: 
Peak of early diastolic (E) and late diastolic (A) flow velocity, E/A 
ratio, deceleration time (Dt) of early filling velocity. 
Colour M mode was used to look for mitral inflow propagation 
velocity. 
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Tissue Doppler imaging (TDI) was performed to look for the 
longitudinal motion of the mitral annulus which has been shown to 
correlate with the rate of myocardial relaxation. The velocity of the mitral 
annulus can be recorded by TDI 
  To assess the diagnostic validity of the results of the 
echocardiogram, a control group for echocardiogram readings was 
incorporated into the study. . 
Echocardiography was undertaken with the same ALOKA 
echocardiogram by the same cardiologist who performed the 
echocardiography in the patients with RA. 
 
STATISTICS 
Data analysis was done using epidemiological information statistical 
software. Using the software the frequencies, mean , standard deviation 
and p values calculated  chi square test and one way anova for quantitative 
variables. p value <0.05 is taken as significant. The correlation between 
various variables were performed using Pearson correlation technique and 
charted on scatter diagram.  
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RESULTS  
Baseline demographics and clinical characteristics 
The study was conducted from December 2010 to November 2011 
recruiting subjects from the Rheumatology Outpatient Clinic of 
Government Rajaji Hospital,  Madurai. A total of 40 RA patients and 20 
control subjects were enrolled during this study period. Women 
outnumbered men in the study population, with 48 women and 12 men. 
TABLE  - 1 
                                                Age Distribution 
Age in years Cases Controls 
17 – 25 2 1 
26 – 35 16 4 
35 – 45 13 10 
 > 45 9 5 
Total 40 30 
Mean 39.0 41.0 
SD 9.64 9.2 
„p‟ value 0.445  Not significant 
  
In our study age of individuals varied between 20 and 60 years. The 
ages of study and control groups were matched. The mean age of study 
group was 39 and that of control group was 41 years.  
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TABLE - 2 
Sex Distribution 
 
Sex Cases Controls 
Male 8 4 
Female 32 16 
Total 40 20 
 
 
Of  the 40 individuals in the study group 32 were women and 8 were men 
in a ratio of 4:1. Similarly in the control group a ratio of 4:1 was 
maintained with 16 individuals being female and 4 being male. 
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TABLE – 3 
Baseline clinical characteristics 
Parameters Cases Control P value 
Age 
Sex: 
Female  
Male 
BMI   
Systolic BP 
Diastolic BP         
39 
 
32 
8 
22.61 
120.0 
80.0 
41 
 
16 
4 
22.40 
120.5 
81.0 
 
0.445 
 
 
 
0.826 
0.854 
0.571 
 
The baseline clinical characteristics listed in table 3 , shows that the 
cases and the control population had similar age and sex distribution, 
similar BMI and blood pressure measurements. There was no statistically 
significant difference between the baseline characteristics of the two 
groups.  
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                                                    TABLE – 4 
Echocardiographic Measurements in RA and Control groups 
 Cases Controls   
 Mean SD Mean SD P value  
E/A 1.135 0.313 1.305 0.182 0.029 Significant 
E/E‟ 8.447         2.32 7.946 0.43 0.344 Not 
Significant 
Dt 180.92 27.77 160.5 11.95 0.003 Significant 
Vp 60.29 10.39 60.45 6.08 0.95  Not 
Significant 
EF% 62.78 5.49 60.80 4.01 0.159 Not 
Significant 
LAVI 23.03 7.53 18.18 2.44 0.007 Significant 
 
[E – early diastolic filling; A- late diastolic filling; Dt – deceleration time of early diastolic 
mitral flow; Vp – flow propagation velocity; EF – ejection fraction; LAVI – left atrial volume 
index]  
Two dimensional echocardiography M – mode and tissue doppler 
studies show that there is no statistically significant difference in ejection 
fraction and propagation velocity of the two groups. Statistical analysis of 
the filling velocities show that there is a statistically significant difference 
between E/A ratios of the two population. The comparison of mean E/e‟ 
ratio between cases and control also show a statistically significant 
difference. However the deceleration time between the two population do 
not show any significant difference. 
 
42 
 
                                         
TABLE - 5 
                   Diastolic dysfunction in RA and Control groups 
 
Grade Cases control P value 
Normal  24 18 0.441 
Grade 1 
Grade 2 
Grade 3 
Prevalence  
10 
6 
0 
40% 
2 
0 
0 
10% 
 
 
0.124            
 
Of the 40 cases evaluated by echocardiography 10 had grade 1 diastolic 
dysfunction and 6 had grade 2 diastolic dysfunction. Of the 20 control subjects 
2 had grade 1 diastolic dysfunction and none had grade 2 dysfunction. 
Comparison between the two is statistically significant.                                                     
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TABLE - 6 
                   Diastolic Dysfunction and  Rheumatoid factor. 
Rheumatoid factor Positive Negative 
Number 
Prevalence of diastolic 
dysfunction 
21 
8 
19 
8 
 
Among 40 cases studied 21 had RF positivity; 8 of these had diastolic 
dysfunction. Remaining 19 were RF negative, 8 of these had diastolic 
dysfunction. There is no stastistically significant difference between these two 
groups. 
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TABLE - 7 
                   Diastolic dysfunction and sex distribution 
Dysfunction No.of cases 
Male 2 
Female 14 
 
Among the study population who had diastolic dysfunction 14 were 
females, 2 were males. 
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Correlation between diastolic parameters and baseline     
characteristics in RA patients. 
                                     TABLE – 8 
Correlation of  L A volume with disease characteristics 
LAV 
Vs 
LAV (Mean – 23.03  SD 7.53) 
Mean S.D. P value 
Age 39.0 9.64  < 0.001 
Duration 4.34 4.23  < 0.001 
DAS 28 4.21 1.31  < 0.001 
ESR 53.6 24.53  < 0.001 
BMI 22.61 3.79  < 0.001 
 
Mean LA volume shows positive correlation with duration of disease, 
ESR and  DAS28 score of the patients. 
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TABLE – 9 
Correlation of E/A ratio with disease characteristics 
 
E/A 
Vs 
E/A  (Mean – 1.135  SD 0.313) 
Mean S.D. P value 
Age 39.0 9.64 < 0.001 
Duration 4.34 4.23 < 0.001 
DAS 28 4.21 1.31 < 0.001 
ESR 53.6 24.53 < 0.001 
BMI 22.61 3.79 < 0.001 
 
The E/A ratio shows positive correlation with the duration of the disease, 
ESR and  DAS28 score of the study population. 
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Table – 10 
Correlation of base line characteristics in RA patients with or without 
diastolic dysfunction 
 Mean  
P value With 
dysfunction 
Without 
dysfunction 
Age 43.75 35.72 0.007 
Duration 5.76 5.28 0.065 
DAS 28 4.69 3.90 0.056 
 
 In case of age, between the two groups there is statistically 
difference.  In case of both duration and disease active score there is 
statistically significant difference between the two groups 
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DISCUSSION 
Introduction : 
Cardiovascular disease has been a well-recognized complication of 
RA for decades(30). Several studies have been performed which show a 
higher prevelance of diastolic dysfunction in this population compared to 
control population. Studies also have been performed to indicate that this 
might precede congestive heart failure by several years which is an 
important  cause for increased mortality among these population 
(15)(5)(18). 
 
Demographics and clinical characteristics : 
Ours was a cross sectional clinic based study carried out on 40 RA  
patients (8 men and 32 women, mean (standard deviation [SD]) age 
39.0(9.64) years, range( 21–50 years). Duration of the disease ranged from 
less than 1 year to 20 years. We had an age and sex matched control 
population of 20 individuals. Both cases and controls belonged to south 
India. These demographics are similar to  a study conducted by 
Udayakumar et.al on same population (south Indian ) which consisted of 
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45 RA(36 women and 9 men) and 45 control subjects, mean age of 34.8 
and a disease duration ranging from 1 to 17 years.(31). 
  
 Echocardiographic measurements and diastolic dysfunction : 
Our study  shows that patients with RA have a higher prevalence of 
diastolic dysfunction (40%) than non-RA subjects (10%) . Diastolic 
dysfunction was more common in RA than in the non-RA subjects even 
after adjustment for or matching for CV risk factors. Doppler 
echocardiogram was the method used to evaluate diastolic function. It 
measured E, A, E/A ratio, DT and IVRT. These parameters were used to 
classify the diastolic dysfunction. Diastolic dysfunction in this study was 
classified according to Redfield(32). The prevalence was similar to 
Udayakumar et al(31) who noted a prevalence of 42.2%. Other  studies 
like Kimberly p Liang et al and Abo Malek Abdul Miuzz et al have 
reported a prevalence of 31% and 47.2% respectively.(33)(34) 
Many studies have compared individual doppler parameters between 
cases and control population. From these study parameters  E and E/A 
ratios were found to be lower in patients with RA compared with the 
control group. The result in this study showed E/A ratio in RA patients 
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was 1.135 (0.822–1.448) and in the control group was 1.305 (1.122–
1.487), which was concordant with the above literature. ( 22)(33)(34). 
Deceleration of inflow of the E wave was measured by deceleration 
time (Dt), which shortened with decreasing LV compliance. A short Dt, a 
marker of increased LV chamber stiffness, has been shown to predict 
cardiovascular (CV) events. In contrast, a longer deceleration time, 
reflective of delayed LV relaxation, has also been shown to predict poor 
CV outcomes(35). Dt in RA patients was longer compared to the control 
population (180 ms ± 27..77vs. 160.5 ms ± 11.95) with a significant p 
value. Wislowska et al(9). reported Dt in RA was longer compared to the 
control group (240 ms ± 23 vs. 219 ms ± 48). 
Tissue Doppler imaging (TDI) was the other method to evaluate 
diastolic function. TDI measures myocardial velocities during the cardiac 
cycle by determining the transmitral flow velocity to annular velocity ratio 
(E/E′ index)(36) TDI was considered more reliable for diagnosing diastolic 
dysfunction(37). In this study E/E′ index of RA patients was 8.447 ± 2.32 
which was higher compared to the study population 7.946+/- 0.43. This 
parameter was noted to be shorter compared to Arslan et al(21) and 
Birdane et al(38). 
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There was no significant difference in propagation velocity in the 
study and control group 60.29+/-10.39 vs 60.45+/- 6.08. 
  LA volume indicates cumulative effects of filling pressures over 
time. LA volume index of 34 mL/m2 is an independent predictor of death, 
heart failure, atrial fibrillation, and ischemic stroke.(40) (43). In our study 
LA volume indexed to body surface area was significantly higher in 
patients of RA compared to study group. It was 23.03+/- 7.53 in study 
group as compared to 18.18+/- 2.44 with a significant p value of 0.007.  
Analysis in RA patients. 
 Further analysis was performed in RA patients to find significant 
values between diastolic dysfunction and normal diastolic function groups. 
We found no statistically significant differences in terms of age of patient, 
duration of RA and ESR. This finding was similar to the study done by 
Gonzalez-Gay et al.,(47) in which their subgroup analysis found there was 
no statistically significant difference in terms of disease duration between 
diastolic dysfunction and normal diastolic function groups. There was also 
no statistically significant difference in prevalence of diastolic dysfunction 
among rheumatoid factor (RF) positive and negative group.  
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Correlation between diastolic dysfunction  and duration of the disease. 
 In this study, there was statistically significant correlation between 
duration of disease and alteration of diastolic function as expressed by E/A 
ratio. There was also significant correlation between duration and LA 
volume index. The study done by Di Franco et al(22). and Montecucco 
et al(41)Arsalan et al(23).(found that there were significant correlations 
between alteration of diastolic function expressed by E/A ratio and disease 
duration of RA. This means that as RA progresses, the prevalence of 
diastolic dysfunction increases as measured by E/A ratio. 
Correlation between diastolic dysfunction and severity of disease 
   DAS-28 was used for objective assessment for RA disease severity. 
The level of ESR was also used to correlate with distolic dysfunction. In 
this study, there was statistically significant correlation between 
echocardiographic measurement values as expressed by E/A ratio and LA 
volume index in RA patients and values of DAS-28 and ESR. This implies 
that  when the severity of the disease is higher the prevalance of diastolic 
dysfunction is also higher. A study done by Maradit-Kremers et al.(42) 
found that RA patients with new onset of heart failure, had a higher ESR 
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level at diagnosis up to 6 months after diagnosis. Kimberly p liang et al( 
33) have found correlation between interleukin-6 (as a marker of disease 
activity) and diastolic dysfunction in RA patients. Certain others such as  
the recently published Abdul Muizz et al have found no significant 
correlation. 
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CONCLUSION 
In conclusion, the prevalence of diastolic dysfunction in RA patients 
attending at the Rheumatology Outpatient Clinic in Government Rajaji 
Hospital, was 40% and prevalence of diastolic dysfunction in the control 
group was 10%. This study showed significant correlations between 
duration of disease, disease severity and echocardiographic measurements. 
Further analysis in RA patients noted  that there were no statistically 
significant differences between diastolic dysfunction and normal diastolic 
function groups in term of duration of disease, blood pressure, ESR. There 
was also no statistically significant association in RA patients in term of 
presence of Rh factor, DAS-28  between diastolic dysfunction and normal 
diastolic function groups. 
This study highlights the need for assessment of diastolic parameters 
in all patients with RA and periodic follow up of the same. Since diastolic 
dysfunction is considered a forerunner for future development of cardiac 
failure in these patients physicians and rheumatologists should be on alert 
and possibly delay this complication by timely intervention. 
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 Prospective clinical and echocardiographic evaluation in RA 
cohorts are needed not only to dissect the importance of disease itself but 
also to learn about the effect of DMARDs and biologicals in retarding this 
process. 
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SUMMARY 
The study “Prevalance of Diastolic Dysfunction in Rheumatoid 
Arthritis ” is a cross- sectional study conducted on patients visiting the 
outpatient Department of Rheumatology ,Government Rajaji Hospital, 
Madurai.  
Forty  patients with rheumatoid arthritis fulfilling the criteria of 
American rheumatologist association criteria ( 1987) were included in the 
study. Twenty age and sex matched control population were selected from 
same population. Inclusion and exclusion criteria were strictly followed in 
selecting case and control cohort.  Selected patients underwent clinical, 
and laboratory evaluation to assess the severity of disease, activity of 
disease and to rule out any associated confounding lab parameters.  DAS 
28 score was calculated as an indicator of  the disease severity. Both case 
and control cohort underwent echocardiography and diastolic parameters 
were assessed. Statistical analysis revealed that the patients with 
rheumatoid arthritis had a higher prevalence of diastolic dysfunction as 
compared to the control population and diastolic dysfunction correlated 
well with the duration of the disease as well as severity of the disease.  
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1 Panchu 35 F none nil nil nil 23.8 110 70 209 217 125 42 2 4.24 neg 
2 Kurshida 43 F none nil nil nil 21.5 120 80 190 170 130 44 1.5 5 neg 
3 Jothimani 40 F none nil nil nil 21.8 110 80 103 132 36 41 15 4.13 pos 
4 ponnusami 38 M none nil nil nil 29.6 110 70 146 150 102 39 9 4.23 pos 
5 valarmati 34 F none nil nil nil 15.8 100 70 160 190 90 44 2.5 4.18 pos 
6 Kripavati 41 F none nil nil nil 34.7 130 80 248 234 140 37 9 3.94 pos 
7 valarmati 48 F none nil nil nil 21.6 110 80 178 150 98 40 0.5 5.77 pos 
8 Muthaiah 33 M none nil nil nil 17.9 110 80 180 160 90 38 2.5 4.77 neg 
9 Kani 33 F none nil nil nil 23.6 120 70 198 165 98 44 0.2 5.73 neg 
10 Meena 28 F none nil nil nil 17.8 130 80 157 133 87 44 3 3.53 pos 
11 Durai 33 M smoker nil nil nil 20.8 120 80 178 144 80 39 1 2.84 pos 
12 Parvati 32 F none nil nil nil 24.5 110 80 165 134 78 42 1 5.05 pos 
13 Pandi 56 M none nil nil nil 21.9 130 80 186 165 89 40 0.5 4.1 neg 
14 Sheela 53 F none nil nil nil 26.8 110 90 202 189 110 39 8 4.17 neg 
15 Shanti 41 F none nil nil nil 24.4 110 80 164 150 88 44 3 3.57 neg 
16 Murugan 42 M none nil nil nil 21.5 120 80 172 144 78 40 8 7.55 neg 
17 Panchavarnam 45 F none nil nil nil 19 140 90 180 160 80 42 20 4.51 neg 
18 Subashini 41 F none nil nil nil 21.5 140 90 170 140 67 36 8 5.3 pos 
19 Periyatchi 55 F none nil nil nil 25.5 140 90 180 164 89 40 10 5.89 pos 
20 Jeyalaxmi 40 F none nil nil nil 26.5 140 90 168 140 80 38 2 2.25 neg 
21 Manimala 55 F none nil nil nil 22.2 130 80 178 150 76 40 0.1 4.6 neg 
22 Ramar 43 M none nil nil nil 18.4 120 80 198 148 128 40 7 5.5 pos 
23 Sumati 41 F none nil nil nil 31.2 130 80 214 190 156 38 6 5.89 pos 
24 Shyamala 53 F none nil nil nil 22.4 120 80 190 176 140 44 5 3.19 pos 
25 Maheswari 53 F none nil nil nil 24.5 110 80 149 186 71 41 1 3.29 neg 
26 Subbulaxmi 28 F none nil nil nil 25.8 110 80 118 124 53 40 2 1.61 neg 
27 Mumtaz 19 F none nil nil nil 21.9 110 70 124 145 65 42 0.5 2.4 pos 
28 Jayanti 28 F none nil nil nil 21.5 110 90 165 140 68 40 4 3.42 pos 
29 Shankar 53 M none nil nil nil 17.1 130 90 205 106 139 45 0.5 5 neg 
30 Nagajoti 28 F none nil nil nil 25.8 130 80 118 124 53 40 2 1.61 neg 
31 Parameswari 45 F none nil nil nil 22.5 120 80 178 160 78 43 4 2.14 pos 
32 Muniamm 29 F none nil nil nil 18.6 120 80 140 98 68 40 5 4.6 neg 
33 Mariamma 33 F none nil nil nil 20.8 110 70 168 134 87 39 8 5.89 pos 
34 Latha 48 F none nil nil nil 23.2 120 80 180 167 110 40 6 6.14 neg 
35 Hema 31 F none nil nil nil 24.6 110 70 178 198 96 42 3 3.29 pos 
36 jJeya 21 F none nil nil nil 19.2 110 70 156 167 78 43 1.5 3.53 pos 
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37 Parasakti 33 F none nil nil nil 21.6 130 80 180 196 120 44 0.5 4.28 pos 
38 Mahalaxm 33 F none nil nil nil 22.4 130 90 172 144 78 40 3 4.51 pos 
39 Ravi 43 M none nil nil nil 18.4 120 70 149 186 71 41 5 3.29 neg 
40 Kamala 32 F none nil nil nil 21.9 120 90 201 179 100 42 3 3.57 neg 
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1 neg 60 yes yes N N 1.38 10 161 60 71 33.98       plus   
2 pos 80 yes yes N N 1.22 5.38 164 58 71 17   plus       
3 neg 38 yes yes LAE N 0.58 6.71 220 48 62 22.14     plus     
4 neg 40 yes yes N N 1.77 13 193 53 57 14.69       plus   
5 neg 45 yes yes N N 1.433 14.87 187 73 73 19.04       plus   
6 pos 70 yes yes LAE N 1.142 10.52 150 70 59 33.96       plus   
7 pos 75 yes yes N N 0.63 8.59 245 85 67 20.98     plus     
8 neg 75 yes yes N N 1.09 8 171 67 59 32.58   plus       
9 neg 100 yes yes N N 0.84 16.16 237 53.3 66 16.48     plus     
10 neg 50 yes yes N N 1.43 5 159 52.5 61 19.79   plus       
11 neg 26 yes yes N N 1.435 8.09 145 64.4 64 32.29   plus       
12 pos 55 yes yes N N 1.44 6 182 56 64 27.4   plus       
13 neg 40 yes yes N N 0.689 7.28 221 48 60 18.79     plus     
14 neg 35 no yes N N 0.78 8 190 52 56 29.44     plus     
15 neg 40 yes yes N N 1.23 7.3 164 63 71 18.2   plus       
16 neg 85 yes yes N N 1 7.62 174 84 68 16.82   plus       
17 neg 40 no yes N N 0.55 6.28 214 56 52 43.8     plus     
18 neg 50 yes yes N N 1.29 7.33 180 50 61 15.03   plus       
19 neg 42 yes yes N N 0.758 10.45 158 41 60 29.8       plus   
20 neg 30 yes yes N N 1.3 11.25 161 60 55 17.96   plus       
21 neg 48 yes yes N N 0.7 9.8 249 47 68 27     plus     
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22 neg 60 yes yes N N 1.166 5.6 200 56 65 19.45   plus       
23 neg 60 yes yes N N 1.02 8.875 220 60 74 12.15   plus       
24 neg 95 yes yes n n 1.01 7.77 196 60 64 11.73   plus       
25 neg 110 no no N N 0.795 11.14 193 60 69 18.39     plus     
26 neg 10 yes yes N N 1.5 7.41 148 82 62 14.75   plus       
27 neg 60 no yes N N 1.5 7.41 160 70 62 19.88   plus       
28 neg 40 yes yes N N 1.11 8 180 68 60 23.35   plus       
29 neg 60 yes yes N N 1.24 6.615 187 60 60 36.45   plus       
30 neg 10 yes yes N N 1.5 7.41 148 82 62 14.75   plus       
31 neg 30 no yes N N 1.2 8.4 168 54 66 18.3   plus       
32 neg 50 yes yes N N 1.3 8.9 170 58 60 22.4   plus       
33 neg 60 no yes N N 0.7 7.41 145 50 60 26.7     plus     
34 pos 120 yes yes N N 0.68 7.62 140 54 58 28.7     plus     
35 neg 25 yes yes N N 1.29 8.33 180 58 60 27.8   plus       
36 neg 40 no yes N N 1.44 8.875 190 64.4 56 29.44   plus       
37 neg 50 yes yes N N 1.3 7.85 161 65 52 17.96   plus   plus   
38 neg 40 yes no N N 1.29 7.33 180 50 61 15.03   plus       
39 neg 60 yes yes N N 1.44 8 182 56 64 27.4   plus       
40 neg 40 yes yes N N 1.23 7.3 164 63 71 29.44   plus       
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1 lakshmi 32 F 120 80 22.6 1.45 6.18 167 67 68 18.78 n       
2 panimalar 28 F 110 70 19.2 1.18 8 160 68 60 16.4 n       
3 ponraj 45 M 130 80 23.4 1.23 6.6 170 66 66 21.9 n       
4 vasanti 49 F 120 80 22.4 1.48 9 186 67 64 18.9 n       
5 kripa 39 F 110 80 20.7 1.63 7.9 156 56 64 17.8 n       
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6 salma 41 F 130 90 28.8 1.18 6.36 140 54 58 19.7 n       
7 muthu 22 F 120 80 18.7 1.26 7 177 67 58 13.78 n       
8 kanimozhi 53 F 130 90 22.7 1.41 7 146 60 58 18.78 n       
9 pandiselvi 33 F 120 80 18.8 1.21 8.67 160 72 62 14.8 n       
10 shajira 54 F 110 80 23.7 0.84 8 150 54 58 22.8   p     
11 vellamma 41 F 120 80 21.6 1.32 8.3 169 56 54 16.9 n       
12 muthiah 42 M 120 80 23.4 1.45 7.22 154 60 62 20.05 n       
13 manimegal 41 F 140 90 21.2 1.38 8.2 144 58 67 17.7 n       
14 parasakti 55 F 130 80 21.8 0.78 7.7 154 52 60 19.8   p     
15 kamala 40 F 110 80 18.7 1.14 7 165 68 63 16.9 n       
16 muniamma53 53 F 120 80 21.1 1.2 8.16 167 58 60 16.3 n       
17 sankarapp 45 M 120 80 24.7 1.72 6.18 176 54 64 22.4 n       
18 anandi 28 F 120 70 20.7 1.23 7.9 156 60 54 16.6 n       
19 amuda 38 F 110 80 26.6 1.08 7.98 149 54 56 15.6 n       
20 ramu 41 M 120 90 27.2 1.22 13.4 164 58 60 17.8 n       
 
